Kazuma Yukihiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kazuma Yukihiro has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Keisuke Goto
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
3 shared publications - Yohei Sekino
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
3 shared publications - Akihiro Goriki
Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
2 shared publications - Hiroyuki Kitano
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
2 shared publications Keisuke Hieda
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
2 shared publications- Kenshiro Takemoto
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
2 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (8)
RIOK2 Promotes Clear Cell Renal Cell Carcinoma Progression Through Cell Cycle Regulation
Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of kidney cancer and is frequently associated with poor clinical outcomes. Ribosome biogenesis, which is upregulated in many malignancies, plays a key role in tumor proliferation. Right open reading frame kinase 2 (RIOK2) is an atypical kinase essential for 40S ribosomal subunit maturation, but its role in ccRCC remains unexplored. We investigated the clinical and biological significance of RIOK2 in ccRCC. Immunohistochemical analysis of 166 ccRCC specimens revealed that high RIOK2 expression was significantly associated with advanced pathological stage, higher tumor grade, and shorter cancer‐specific and progression‐free survival. Public datasets confirmed the elevated RIOK2 mRNA expression in ccRCC, and its association with poor prognosis. Functional studies demonstrated that RIOK2 knockdown suppressed the proliferation, invasion, and migration of ccRCC cells. RNA sequencing, followed by gene set enrichment analysis, revealed that RIOK2 knockdown led to the downregulation of cell cycle‐related pathways, including E2F targets. Analyses of public datasets further highlighted suppression of the G2/M checkpoint. Flow cytometry revealed G1 cell cycle arrest accompanied by reduced CDK2 protein expression in RIOK2‐knockdown cells. Furthermore, the small‐molecule RIOK2 inhibitor, NSC139021, suppressed ccRCC cell proliferation in a dose‐dependent manner, with reduced efficiency in RIOK2‐knockdown cells. Collectively, these findings identify RIOK2 as a clinically relevant factor associated with aggressive disease behavior and cell‐cycle regulation in ccRCC.
- 5 August 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (8)
Open AccessRIOK2 Promotes Clear Cell Renal Cell Carcinoma Progression Through Cell Cycle Regulation
Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of kidney cancer and is frequently associated with poor clinical outcomes. Ribosome biogenesis, which is upregulated in many malignancies, plays a key role in tumor proliferation. Right open reading frame kinase 2 (RIOK2) is an atypical kinase essential for 40S ribosomal subunit maturation, but its role in ccRCC remains unexplored. We investigated the clinical and biological significance of RIOK2 in ccRCC. Immunohistochemical analysis of 166 ccRCC specimens revealed that high RIOK2 expression was significantly associated with advanced pathological stage, higher tumor grade, and shorter cancer‐specific and progression‐free survival. Public datasets confirmed the elevated RIOK2 mRNA expression in ccRCC, and its association with poor prognosis. Functional studies demonstrated that RIOK2 knockdown suppressed the proliferation, invasion, and migration of ccRCC cells. RNA sequencing, followed by gene set enrichment analysis, revealed that RIOK2 knockdown led to the downregulation of cell cycle‐related pathways, including E2F targets. Analyses of public datasets further highlighted suppression of the G2/M checkpoint. Flow cytometry revealed G1 cell cycle arrest accompanied by reduced CDK2 protein expression in RIOK2‐knockdown cells. Furthermore, the small‐molecule RIOK2 inhibitor, NSC139021, suppressed ccRCC cell proliferation in a dose‐dependent manner, with reduced efficiency in RIOK2‐knockdown cells. Collectively, these findings identify RIOK2 as a clinically relevant factor associated with aggressive disease behavior and cell‐cycle regulation in ccRCC.
- Open Access
- 30 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Clinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma
Primary resistant disease (PRD) to immuno-oncology plus vascular endothelial growth factor receptor inhibitor (IOVE) therapy is a critical unmet need in metastatic renal cell carcinoma (mRCC), yet its clinical and molecular features remain poorly defined. We provide the first integrated clinical and genomic characterization of PRD, combining two complementary, non-overlapping cohorts: a real-world clinical cohort of 159 patients (Hiroshima Cancer Registry Project, H-CARP) and a national genomic database (Center for Cancer Genomics and Advanced Therapeutics, C-CAT). PRD (n = 20 [12.6%]) defined a distinct high-risk group with markedly shorter progression-free survival, PFS2, and overall survival (OS) and a median OS of 8.5 months. Notably, liver metastasis was a strong, readily available independent predictor of PRD (odds ratio 4.99; p = 0.011), enabling early risk stratification, and non-clear cell histology was enriched among PRD. The comparable OS with or without subsequent therapy underscores an urgent need for novel strategies. Exploratory genomic profiling revealed candidate, hypothesis-generating correlates of resistance (lower VHL and PBRM1; higher TSC2 and MSH3 alterations). By linking real-world outcomes with national genomic data, this study establishes a foundation for early identification and biomarker-guided management of PRD.
- 30 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessClinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma
Primary resistant disease (PRD) to immuno-oncology plus vascular endothelial growth factor receptor inhibitor (IOVE) therapy is a critical unmet need in metastatic renal cell carcinoma (mRCC), yet its clinical and molecular features remain poorly defined. We provide the first integrated clinical and genomic characterization of PRD, combining two complementary, non-overlapping cohorts: a real-world clinical cohort of 159 patients (Hiroshima Cancer Registry Project, H-CARP) and a national genomic database (Center for Cancer Genomics and Advanced Therapeutics, C-CAT). PRD (n = 20 [12.6%]) defined a distinct high-risk group with markedly shorter progression-free survival, PFS2, and overall survival (OS) and a median OS of 8.5 months. Notably, liver metastasis was a strong, readily available independent predictor of PRD (odds ratio 4.99; p = 0.011), enabling early risk stratification, and non-clear cell histology was enriched among PRD. The comparable OS with or without subsequent therapy underscores an urgent need for novel strategies. Exploratory genomic profiling revealed candidate, hypothesis-generating correlates of resistance (lower VHL and PBRM1; higher TSC2 and MSH3 alterations). By linking real-world outcomes with national genomic data, this study establishes a foundation for early identification and biomarker-guided management of PRD.
- Open Access
- 30 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (5) , 102568
Comprehensive Analysis of Tumor Mutational Burden in Prostate Cancer: Multipublic Dataset Analysis
- 30 April 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (5) , 102568
Open AccessComprehensive Analysis of Tumor Mutational Burden in Prostate Cancer: Multipublic Dataset Analysis
- Open Access
- 9 August 2025
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (11) , 663.e1-663.e9
Modified Glasgow prognostic score predicts outcomes of tyrosine kinase inhibitor monotherapy and immune checkpoint inhibitor combination therapy for metastatic renal cell carcinoma
- 9 August 2025
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (11) , 663.e1-663.e9
Open AccessModified Glasgow prognostic score predicts outcomes of tyrosine kinase inhibitor monotherapy and immune checkpoint inhibitor combination therapy for metastatic renal cell carcinoma